niftify.in

The Economic Times

CCI clears Rs 13,630 cr Mankind Pharma acquisition of Bharat Serums

The Competition Commission of India (CCI) has approved Mankind Pharma's ₹13,630-crore acquisition of Bharat Serums and Vaccines. This acquisition will strengthen Mankind's position in the Indian women's health and fertility drug market. Mankind Pharma and Bharat Serums both specialize in pharmaceutical formulations and healthcare products.

Business Standard

CCI approves Mankind Pharma's purchase of Bharat Serums for $1.6 bn

Mankind Pharma, which has brands including Manforce condoms and Prega News pregnancy tests, signed an agreement to acquire Bharat Serums

Business Line

CCI approves Mankind Pharma’s acquisition of Bharat Serums and Vaccines

Deal involves Mankind buying 100 per cent equity in Bharat Serums from PE firm Advent International at an enterprise value of ₹13,630 crore

Mint

Mankind Pharma secures CCI approval for ₹13,360-crore worth acquisition of Bharat Serums and Vaccines

The Competition Commission of India has approved Mankind Pharma's ₹13,630 crore acquisition of Bharat Serums and Vaccines.

The Economic Times

CCI clears Rs 13,630-cr Mankind Pharma-Bharat Serums Vaccines deal

The Competition Commission of India has approved Mankind Pharma's Rs 13,630 crore acquisition of Bharat Serums and Vaccines. This acquisition, which includes a 100% stake, advances Mankind Pharma's position in the women's health and fertility drug market and grants access to critical care products with established R&D platforms.

Business Line

Mankind Pharma transfers OTC biz to subsidiary Mankind Consumer Products

The company’s portfolio includes several trusted brands Manforce, HealthOK, Prega News, AcneStar, Unwanted and Gas-O-Fast across categories such as wellness, hygiene, and personal care

CNBC TV18

Stocks to watch on Oct 1: Tata Power, Jindal Stainless, Mankind Pharma and more

Kick off October with some must-watch stocks! On Tuesday, Tata Power, Jindal Stainless, Mankind Pharma, among others will be in focus.

The Economic Times

Mankind Pharma to raise Rs 10,000 crore through NCDs, CPs to fund BSV deal

The company will raise up to Rs 5,000 crore through non-convertible debentures (NCDs) maturing in up to 48 months, according to a regulatory filing.

Business Standard

Mankind Pharma board approves fundraising plan of up to Rs 10,000 cr

Mankind Pharma on Monday said it will raise up to Rs 10,000 crore via issuance of non-convertible debentures and commercial papers. The company said its board has approved to raise up to Rs 5,000 crore via non-convertible debentures in 3-4 distinct series with maturities of up to 48 months. The board's fundraising committee also approved to raise up to Rs 5,000 crore via listed and rated commercial papers, having face value as may be decided in accordance with applicable law, in one or more tranches or series, the drug maker said in a regulatory filing. The company, however, did not disclose how it aims to utilise the raised capital. In July this year, Mankind had announced the acquisition of Bharat Serums and Vaccines from Advent International for around Rs 13,630 crore. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and consumer healthcare products. Shares of the company on Monday ended 2.68 per cent down at Rs .

Business Line

Mankind Pharma to raise up to ₹10,000 crore via NCDs and CPs, shares dip

Specific coupon rates, allotment dates, and maturity dates for the instruments yet to be determined

CNBC TV18

Mankind Pharma board approves raising up to ₹10,000 crore via NCDs, commercial paper

Mankind Pharma will list the NCDs on the Bombay Stock Exchange. The date of allotment and the final date of maturity will be updated at the time of the allotment. Coupon rate on these NCDs will also be determined later.

Business Line

Stock to buy today: Mankind Pharma (₹2,651.30): BUY

Mankind Pharma share price can rise to ₹2,750 and ₹2,850

Business Standard

Mankind Pharma board OKs to raise Rs 10,000 cr

Mankind Pharma said that its board approved to raise funds aggregating to Rs 10,000 crore through non convertible debentures (NCDs) and commercial papers (CPs) on private placement basis.

The Economic Times

Mankind Pharma board approves raising Rs 10,000 crore through NCDs

The board has established a fundraising committee and granted them the authority to manage all aspects of raising funds, such as deciding the terms for issuing and allotting NCDs and CPs, and handling other relevant tasks.

CNBC TV18

Mankind Pharma to raise up to ₹10,000 crore through NCDs

To facilitate this process, the board has constituted a Fund Raising Committee. Shares of Mankind Pharma Ltd ended at ₹2,547.15, up by ₹116.15, or 4.78%, on the BSE.

Business Standard

Mankind Pharma to raise funds up to Rs 10k crore via debt instruments

The board announced the issuance of corporate guarantees for four of its subsidiaries, namely Mankind Agritech, Appian Properties, Copmed Pharmaceuticals, and Lifestar Pharma.

Business Line

Broker’s call: Mankind Pharma (Buy)

Investec

CNBC TV18

Mankind Pharma shares surge to a record high after Investec projects 35% upside

Investec mentioned that Mankind Pharma's vision to be an innovation-driven and differentiation-focused company with high entry barrier products has found a match in Bharat Serums and Vaccines (BSV).

Business Standard

Mankind Pharma board to consider fund raising on Sep 20

The pharma major informed that a meeting of its board is scheduled to be held on Friday, 20 September 2024 to mull the fund raising proposal for an amount as may be decided.

The Economic Times

Stocks in news: VST Industries, Torrent Power, REC, Tata Power, Mankind Pharma

Torrent Power has received Letter of Intent (LOI) from Maharashtra State Electricity Distribution Co. Limited (MSEDCL) for procurement of 1,500 MW/ 12,000 MWh energy storage capacity for pumped hydro storage project.

The Economic Times

Mankind Pharma board to meet this week to consider fund raising

Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and consumer healthcare products.

CNBC TV18

Mankind Pharma to consider fund raising plans on September 20

Shares of Mankind Pharma ended 0.2% lower at ₹2,452.00 per share.

The Economic Times

Block deals worth over Rs 10,934 crore this week. Trent, Mamaearth, Patanjali Foods among stocks with major action

Nifty closed the week with 2% gains, despite significant block deals totaling Rs 10,934 crore across large, mid, and smallcap companies. Tata Group's Trent led largecap block deals with Rs 715 crore, followed by Mankind Pharma, Tube Investments of India, Bosch, and others.

CNBC TV18

Mankind Pharma transfers OTC business to unit via slump sale agreement

Under the deal, Mankind Pharma will divest its OTC business, which includes a range of non-prescription products, to Mankind Consumer Products.

CNBC TV18

GIC Re, GSK Pharma, Godfrey Phillips, IEX and more: Top stocks to watch out for on September 4

stocks to watch, GIC Re, GSK Pharma, Godfrey Phillips, IEX, Zydus Lifesciences, KIMS, AU Small Finance Bank, PDS, ZEEL, Hitachi Energy, NHPC, Mankind Pharma and more, these are the stocks to watch for today.

The Economic Times

Mankind: How Meerut brothers built India's 4th largest pharma firm

Mankind Pharma has announced a significant move by acquiring Bharat Serums and Vaccines Ltd for Rs 13,630 crore. The acquisition, partly funded by debt, aims to strengthen Mankind’s portfolio. The Juneja brothers are confident in their strategy despite market concerns about integration and cost.

Business Standard

Mankind up 3% after reports say co looking to raise Rs 9k cr for BSV deal

Mankind Pharma is likely to raise Rs 9,000 crore through NCDs to acquire Bharat Serums and Vaccines

Business Standard

Mankind Pharma plans Rs 9,000 crore raise for Bharat Serums acquisition

The move will position Mankind as a leader in the gynaecology-fertility segment, with an anticipated market share of around 20%, surpassing Emcure

The Economic Times

Mankind Pharma eyes ₹9,000 cr via debt to stitch BSV deal

The average blended cost of the debt is likely to be around 8.50% with the firm seeking to borrow money over one- to-five years, said three people familiar with the plans. "Bankers have already approached large mutual funds to place the debt, which will range from one year and may go up to five years looking at the demand," said one of the persons.

Mint

Pharma stocks see 3rd straight month of gains in August, Mankind Pharma and 6 others rise up to 23%

Pharma stocks continued their bullish trend in August, with the Nifty Pharma index rising by 6.61%, driven by strong performances from Mankind Pharma and others. The index has gained 36% this year, benefiting from increased US sales, new product launches, and strong quarterly earnings.

Business Line

Broker’s call: Mankind Pharma (Buy)

Motilal Oswal

The Economic Times

Mankind can clear debt taken for BSV buy in 3 years: MD Rajeev Juneja

Mankind Pharma aims to clear its ₹13,630-crore debt from acquiring Bharat Serums and Vaccines within three years, according to MD Rajeev Juneja. He was optimistic about using Mankind's reach and marketing skills to expand BSV's range. The successful integration of Panacea in 2022, despite initial doubts, was cited as a positive precedent.

The Economic Times

Delhi High Court urges quick decision on Mankind Pharma's plea against Mercykind Pharmaceuticals

The Delhi High Court instructed its single judge bench to swiftly reconsider Mankind Pharma's request to block Chandra Mani Tiwari from using the name Mercykind Pharmaceuticals. The court took note of alleged 'dishonest adoption' and changes in Tiwari's branding. Mankind Pharma had sought this due to trademark concerns but was previously denied an injunction in 2018.

Mint

Torrent, Glenmark, Alkem, Mankind, Lupin among key drivers of Indian pharma market growth during July

Stock Market Today: Torrent Pharmaceuticals, Glenmark Pharmaceuticals, Mankind, Lupin, Alkem Laboratories were among key drivers of pharma market growth during July. Indian pharma market growth remained tepid at 6.1% suggest reports

Business Standard

Oyo founder Ritesh Agarwal invests Rs 830 cr in firm's latest funding round

Besides Agarwal, key contributors in the funding round include InCred Wealth, J&A Partners, the family office of Mankind Pharma promoters and ASK Financial Holdings

Hindustan Times

OYO raises ₹1,457 crore in latest funding round for growth and global expansion

OYO raises ₹1,457 crore including contributions from InCred Wealth, J&A Partners, the family office of Mankind Pharma promoters and ASK Financial Holdings.

Business Line

What should you do with the Mankind Pharma stock post the Bharat Serums and Vaccines acquisition?

Synergies arising from the Bharat Serums acquisition could play out over the long term, benefitting Mankind shareholders

The Economic Times

Mankind Pharma in licensing pact with Takeda to market acidity drug Vonoprazan in India

Mankind Pharma partners with Takeda to introduce Vonoprazan for GERD, oesophagitis, ulcers, and Helicobacter pylori in India. EVP Ramesh stresses business growth. Collaborations with AstraZeneca (Symbicort) and Novartis (Neptaz) enhance their strategy. In-licensing, including royalties on sales, expands domestic formulations using local sales networks, improving access to innovative therapies.

Business Standard

CPPIB sells stakes in Delhivery, Nykaa; Capital Group in Mankind

Canada Pension Plan Investment Board pared its holdings on Wednesday, in FSN E-Commerce Ventures (Nykaa) and Delhivery

Business Line

Mankind Pharma front-runner to buy Bharat Serums, binding bids yet to be submitted

From a 52-week low of ₹1,661.05 in July 2023, the company’s shares rose to a high of ₹2,490 in April 2024, though it has come off those highs now